Ashland (ASH) Q3 Revenue Falls 15%
(NYSE:ASH), a global specialty chemicals company known for its additives and functional ingredients used in pharmaceuticals, personal care, coatings, and other industries, reported third quarter fiscal 2025 earnings on July 29, 2025. The quarter’s central news was a notable year-over-year decline in both revenue and adjusted EBITDA, with revenue falling below analysts’ forecasts. Revenue (GAAP) of $463 million missed consensus by $13.6 million, while non-GAAP EPS from continuing operations was $1.04, falling short of the $1.20 consensus. Management’s updated guidance narrowed expectations for full-year revenue and adjusted EBITDA, projecting results toward the low end of prior outlooks and signaling caution amid persistent end-market softness and macro uncertainty.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report.
Ashland operates as a specialty materials provider, serving varied markets such as pharmaceuticals (offering excipients for tablets and injectables), personal care (including skin and hair product additives), coatings (additives for paint and construction), and industrial materials. Its strength lies in formulating performance-enhancing ingredients that help its customers meet stringent regulatory, safety, and quality requirements.
Source Fool.com
Ashland Inc. Stock
Ashland Inc. is currently one of the favorites of our community with 10 Buy predictions and no Sell predictions.
As a result the target price of 63 € shows a positive potential of 30.71% compared to the current price of 48.2 € for Ashland Inc..